Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Daclatasvir - Bristol-Myers Squibb

Drug Profile

Daclatasvir - Bristol-Myers Squibb

Alternative Names: BMS-790052; Daklinza; DCV

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AmeriCares; Bristol-Myers Squibb
  • Developer Bristol-Myers Squibb; Vertex Pharmaceuticals
  • Class Antivirals; Biphenyl compounds; Carbamates; Imidazoles; Pyrrolidines; Small molecules
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hepatitis C

Most Recent Events

  • 29 Dec 2022 No development reported - Phase-II for Hepatitis C (Combination therapy, In adolescents, In children, Treatment-naive, Treatment-experienced) in Poland, Australia (PO)
  • 17 Sep 2020 Bristol-Myers Squibb terminates a phase II trial in Hepatitis C (Combination therapy, In adolescents, In children, Treatment-naive, Treatment-experienced) in Australia, Poland, Germany, Spain and Taiwan, due to change in business objectives (NCT03487848) (EudraCT2017-003338-94)
  • 07 Jun 2018 Discontinued - Phase-II for Hepatitis C (Combination therapy, Treatment-naive) in Egypt (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top